导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.67% | 1575/4773 |
| 近一周 | -0.93% | 1412/5465 |
| 近一月 | -3.67% | 2737/5421 |
| 近一季 | -9.47% | 3578/5231 |
| 近半年 | -5.05% | 2980/4920 |
| 近一年 | 6.93% | 1534/4394 |
| 近两年 | 71.75% | 988/2954 |
| 近三年 | 38.53% | 802/2253 |
| 成立以来 | 28.60% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.85% 1156/4961 |
19.36% 1304/5312 |
- - |
- - |
| 2025 | 31.09% 1267/4813 |
2.06% 1477/3635 |
1.98% 1975/4076 |
25.46% 1398/4524 |
0.39% 2019/4813 |
| 2024 | 7.15% 1687/3463 |
-1.79% 1277/2808 |
-5.08% 1640/3014 |
15.59% 1676/3129 |
-0.56% 1462/3463 |
| 2023 | -5.71% 765/2656 |
7.99% 505/2280 |
-4.18% 1082/2385 |
-4.37% 1125/2515 |
-4.71% 1151/2655 |
| 2022 | -18.55% 725/2207 |
-13.47% 766/1919 |
3.04% 1227/2016 |
-10.66% 438/2113 |
2.26% 998/2208 |
| 2021 | 14.33% 338/1822 |
-1.99% 567/1255 |
9.25% 575/1330 |
4.05% 385/1466 |
2.62% 551/1822 |
| 2020 | - - |
- - |
- - |
-7.54% 1132/1164 |
2.69% 972/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 兴业中证500ETF VS. 长安沪深300非周期A(740101) |